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Summary
Background Home HIV counselling and testing (HTC) achieves high coverage of testing and linkage to care compared 
with existing facility-based approaches, particularly among asymptomatic individuals. In a modelling analysis we 
aimed to assess the eﬀ ect on population-level health and cost-eﬀ ectiveness of a community-based package of home 
HTC in KwaZulu-Natal, South Africa.
Methods We parameterised an individual-based model with data from home HTC and linkage ﬁ eld studies that 
achieved high coverage (91%) and linkage to antiretroviral therapy (80%) in rural KwaZulu-Natal, South Africa. Costs 
were derived from a linked microcosting study. The model simulated 10 000 individuals over 10 years and incremental 
cost-eﬀ ectiveness ratios were calculated for the intervention relative to the existing status quo of facility-based testing, 
with costs discounted at 3% annually.
Findings The model predicted implementation of home HTC in addition to current practice to decrease HIV-
associated morbidity by 10–22% and HIV infections by 9–48% with increasing CD4 cell count thresholds for 
antiretroviral therapy initiation. Incremental programme costs were US$2·7 million to $4·4 million higher in the 
intervention scenarios than at baseline, and costs increased with higher CD4 cell count thresholds for antiretroviral 
therapy initiation; antiretroviral therapy accounted for 48–87% of total costs. Incremental cost-eﬀ ectiveness ratios per 
disability-adjusted life-year averted were $1340 at an antiretroviral therapy threshold of CD4 count lower than 
200 cells per μL, $1090 at lower than 350 cells per μL, $1150 at lower than 500 cells per μL, and $1360 at universal 
access to antiretroviral therapy.
Interpretation Community-based HTC with enhanced linkage to care can result in increased HIV testing coverage 
and treatment uptake, decreasing the population burden of HIV-associated morbidity and mortality. The incremental 
cost-eﬀ ectiveness ratios are less than 20% of South Africa’s gross domestic product per person, and are therefore 
classed as very cost eﬀ ective. Home HTC can be a viable means to achieve UNAIDS’ ambitious new targets for HIV 
treatment coverage.
Funding National Institutes of Health, Bill & Melinda Gates Foundation, Wellcome Trust.
Copyright © Smith et al. Open Access article distributed under the terms of CC BY.
Introduction
Expansion of the use of antiretroviral therapy is a major 
component of approaches to control the HIV epidemic, 
particularly vital in sub-Saharan Africa, where about 
1·5 million new HIV infections occur each year.1 How-
ever, despite the high burden of disease, only a third of 
adults in sub-Saharan Africa have been tested for HIV in 
the past year, and less than a third of those testing 
positive receive antiretroviral therapy.2–5 Antiretroviral 
therapy substantially reduces HIV-associated morbidity 
and mortality and reduces the risk of transmission to 
susceptible partners by up to 96% through suppression 
of viral replication.6–9 For HIV treatment programmes, 
cost-eﬃ  cient HIV counselling and testing (HTC) and 
approaches that link patients to care are urgently needed 
to prevent morbidity and mortality.
Traditional facility-based HTC, including voluntary 
counselling and testing and provider-initiated counselling 
and testing, has not attained high coverage of testing or 
antiretroviral therapy uptake in sub-Saharan Africa and 
will probably be insuﬃ  cient to meet the ambitious 
90-90-90 target set by UNAIDS, which aims by 2020 for 
90% of HIV-infected individuals to be diagnosed, 90% of 
patients with a diagnosis to have initiated treatment, and 
90% of those to be virally suppressed.10 Coverage of 
testing varies substantially by country. For example, 
ﬁ ndings from recent studies have shown that 17% of 
men and 17% of women in Nigeria, 36% and 47% in 
Kenya, 51% and 72% in Malawi, and 65% and 68% in 
South Africa had been tested in the previous 12 months 
and received their results.11–14 Furthermore, national 
coverage rates often mask large subnational variation. 
Barriers to HIV testing include economic costs for 
patients (transportation, waiting time, childcare), 
concerns about conﬁ dentiality, and low perceived risk of 
HIV infection.15 The policy of antiretroviral therapy 
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eligibility at a CD4 count of 350 cells per μL or lower 
might have also encouraged providers and people living 
in the community to wait until they are clinically ill 
before seeking testing or treatment. Moreover, many 
clinics have poor linkage to treatment for individuals 
tested and found eligible.16
Community-based HTC (ie, HTC outside of facilities), 
which includes home-based, door-to-door, and mobile-
van testing,10 reaches more ﬁ rst-time testers and HIV-
positive individuals with high CD4 cell counts than does 
facility-based HTC. Community-based HTC also relies 
less heavily on existing infrastructure, allowing for easier 
scale-up.10 Community HTC with mobilisation and 
enhanced linkage to care has the potential to overcome 
barriers to HIV testing and linkage to care, achieving 
widespread coverage of testing and antiretroviral 
therapy.2,17,18 Strategies for community HTC and linkage 
have high acceptability and lead to greater uptake of 
testing, linkage to care, and viral-load suppression than 
does facility-based HTC.10,19–21 Large community-
randomised controlled trials are underway to assess the 
eﬀ ect of home HTC with enhanced linkage to care on 
uptake of antiretroviral therapy and HIV incidence.21–24 
However, key questions remain about the aﬀ ordability 
and cost-eﬀ ectiveness of community HTC compared 
with current practice.
The costs of community-based HTC vary by country, 
testing method, and HIV prevalence. Published cost 
estimates for sub-Saharan Africa range from US$2·45 per 
person tested in Malawi (cost of testing supplies only) to 
between $81·72 and $126·48 in South Africa (cost of 
testing supplies, personnel, utilities, training, buildings, 
oﬃ  ce equipment, and publicity for church-based 
HTC).25,26 Mobile HTC with point-of-care CD4 testing in 
South Africa ranged from $29·30 to $31·30 and facility-
based testing ranged from $9·30 in South Africa to 
$29·56 in Kenya for testing at a ﬁ xed HTC site.27,28 
Accurate cost data are crucial for estimating potential 
budgetary eﬀ ects of implementing widespread HTC and 
linkage programmes.
Home HTC with point-of-care CD4 testing (with the 
PIMA analyser [Alere, Waltham, MA, USA]) and lay 
counsellor follow-up visits to encourage linkage to care 
can achieve high HTC coverage (91%), linkage to care 
(90%), and antiretroviral therapy initiation (80% of those 
eligible) in the high-HIV-prevalence setting of KwaZulu-
Natal, South Africa.19,29 Early diagnosis and treatment 
reduces morbidity, mortality, and onwards transmission.6–9 
We postulated that, despite the extra resources needed to 
implement these changes, a home HTC package including 
community mobilisation and sensitisation, point-of-care 
CD4 testing, screening for clinical indicators for 
antiretroviral therapy initiation, and follow-up visits by a 
community health worker (to support uptake of 
antiretroviral therapy and adherence) could avert 
additional morbidity and mortality compared with existing 
programmes. In this health economic modelling analysis, 
we aimed to estimate the population-level health eﬀ ects of 
home HTC with facilitated linkage to care, and then use 
costing data from our previous studies of home HTC and 
care linkages to estimate the costs, cost-eﬀ ectiveness, and 
feasibility of a home HTC intervention under simulated 
expansion of eligibility criteria for antiretroviral therapy.
Methods
Mathematical model
We parameterised an individual-based mathematical 
model with demographic, behavioural, and treatment 
uptake data from two studies of home HTC done in rural 
KwaZulu-Natal and calibrated to HIV incidence from a 
population survey (appendix).18,19,30,31 The full model 
speciﬁ cation is available in the appendix. Brieﬂ y, the 
model simulated a community of 1300 households with a 
total mean population size of 10 000 adults aged 18 years 
and older, capturing the characteristics (sex, age, and 
position in the household) of individuals enumerated in 
the home HTC project. Sexual behaviour, partnership 
formation and dissolution, and seasonal migration for 
work were distributed according to these characteristics. 
Children and teenagers enumerated in the pilot survey 
entered the model as they reached 18 years of age and all 
individuals in the model were subject to an age-speciﬁ c 
and sex-speciﬁ c background mortality rate (non-HIV-
related) consistent with that in South Africa before the 
onset of the HIV epidemic.32
Sexual partnerships could be formed between any two 
adults of the opposite sex with a tendency for the male 
partner to be slightly older than the female partner 
(modal age diﬀ erence 0–4 years in the study; unpublished 
data). Long-term partnerships had a mean duration of 
7·15 years and could only be formed within the 
community. Short-term partnerships had a mean 
duration of 3 months and were preferentially formed 
with adults in the community; if none were available, 
short-term partners outside the community could be 
simulated. Adults outside the community were not 
explicitly modelled but had a probability of HIV infection 
based on the age and sex distribution of HIV prevalence 
reported in the home HTC studies. Individuals could 
have a maximum of two concurrent partners at any time, 
only one of which could be long-term.
HIV transmission was assumed to vary by sex, CD4 cell 
count (as a correlate of infection stage and viral load), 
antiretroviral therapy status of the HIV-infected partner, 
coital frequency (which varies according to partnership 
type), condom use, male circumcision, and co-infection 
with sexually transmitted infections of either partner. 
Condom use was distributed by partnership type and 
HIV status (appendix) and could change with long-term 
partnership formation or dissolution or a positive HIV 
test. After HIV infection, the model tracked fall in CD4 
cell count for individuals through to death.
We assigned disability-adjusted life-years (DALYs) to 
each HIV-related health state, and summed them over all 
See Online for appendix
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individuals for the duration of the model run (appendix).33 
All scenarios started with the reported coverage of 
antiretroviral therapy of 32% among all HIV-positive 
individuals in the community at baseline. For both the 
intervention and non-intervention scenarios, we 
modelled four initiation thresholds for antiretroviral 
therapy: CD4 count 200 cells per μL or lower, 350 cells 
per μL or lower, 500 cells per μL or lower, and universal 
antiretroviral therapy (in which all HIV-positive people 
would be eligible for treatment).
Procedures
In the status quo scenario (ie, without the intervention), 
the model simulated existing uptake of HIV testing and 
antiretroviral therapy to match the empirical data 
reported from the study at baseline.19 Individuals had a 
monthly probability of HTC that depended on their sex, 
infection status, and CD4 cell count if infected (appendix). 
For uninfected individuals, repeat HIV testing could 
occur a minimum of 1 year after a negative test, with the 
same monthly probability as initial testing. After a 
positive test, HIV-positive individuals had a monthly 
probability of linking to care that depended on their CD4 
cell count (ﬁ gure 1, appendix).
Once linked, we assumed that individuals were in 
regular pretreatment care and initiated antiretroviral 
therapy after a mean wait of 1·23 months after they 
became eligible. No diﬀ erence in uptake rates for 
treatment were reported between individuals with CD4 
counts of 200 cells per μL or lower and those with counts 
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Figure 1: Flow diagram of HIV disease progression and the HIV care cascade among HIV-positive individuals
HIV-positive individuals progress through HIV disease stages and on to HIV-related death at rates σ (top to bottom); subscripts indicate the CD4 cell count category to 
which the rate applies. Infected individuals (and uninfected, not shown here) are tested at rate ρ, attend clinics for CD4 staging and other clinical tests at rate δ, and 
initiate antiretroviral therapy at rate ε. Antiretroviral therapy dropout occurs at rate ψ irrespective of CD4 category at antiretroviral therapy initiation and individuals 
return to their previous CD4 count unlinked to care. Home HTC acts by instantaneously moving all eligible and untested individuals into the tested compartments, 
increasing rate δ for clinic visits, increasing rate ε for antiretroviral therapy initiation, and decreasing rate ψ for antiretroviral therapy dropout. Rate changes last for 
1 year post-intervention, after which treatment-seeking behaviour reverts to the status quo. Note that HIV infection, HIV testing by uninfected individuals, natural 
mortality, and mortality on antiretroviral therapy are not shown here. HTC=HIV counselling and testing. ART=antiretroviral therapy.
Research model Operational model
HIV negative HIV positive HIV negative HIV positive
Personnel $14·86 $20·10 $5·58 $9·72
Transportation $1·83 $2·47 $1·14 $2·61
Equipment $0·18 $0·25 $0·11 $0·19
Supplies $1·76 $9·94 $0·93 $9·14
Buildings and overhead $0·89 $1·20 $0·52 $0·91
Start-up $0·36 $0·49 $0·10 $0·18
Recurring meetings $0·23 $0·32 $0·12 $0·21
Data capture and use $0·48 $0·65 $0·19 $0·42
Total (annualised) $20·59 $35·42 $8·70 $23·37
Table shows per-person costs of HIV testing and linkage through home HTC in 2012 US$. The operational model 
removes research costs and outputs, incorporates increased testing eﬃ  ciency from time-and-motion studies, and 
assumes task shifting from professional counsellors to community care workers.
Table 1: Unit costs for the household testing intervention
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of 201–350 cells per μL in the ﬁ eld studies (data not 
shown), so we assumed that the mean wait for treatment 
remained constant when the threshold for treatment 
initiation changed to 350 cells per μL or lower. At higher 
eligibility criteria, we assumed longer wait times for 
individuals with CD4 counts of 351 cells per μL and above, 
on the assumption these individuals would be less likely 
to link to care than would those below the threshold;29,30 
we conservatively assumed the monthly probability of 
antiretroviral therapy initiation for eligible individuals in 
pretreatment care (initially 6·5% per month) to halve for 
individuals with CD4 counts of 351–500 cells per μL and 
quarter for those with CD4 counts higher than 500 cells 
per μL (ﬁ gure 1, appendix). In ﬁ eld studies we noted very 
few people initiating antiretroviral therapy with CD4 cell 
counts above the initiation criteria (data not shown), so in 
the model we assumed that only individuals with counts 
below that threshold could start treatment.
Home HTC was added to the status quo scenario at 
91% coverage,19 repeated every 4 years (on the basis of 
ﬁ ndings from previous modelling analyses34), and 
resulted in an immediate HIV test and increased 
probability of linkage to care for HIV-positive individuals 
(monthly probability of 67% irrespective of CD4 count). 
At antiretroviral therapy eligibility criteria of 200 cells 
per μL or lower and 350 cells per μL or lower, we 
assumed the probability of treatment initiation for 
eligible individuals after home HTC to be 30% per 
month (ﬁ tted to data from the ﬁ eld studies). We used the 
same assumption as the status quo scenario when 
simulating higher criteria; the monthly probability of 
treatment initiation for eligible individuals in 
pretreatment care was assumed to halve for individuals 
with CD4 counts of 351–500 cells per μL and quarter for 
those with CD4 counts higher than 500 cells per μL 
(appendix). These changes lasted for 1 year after the 
intervention, after which testing and treatment-seeking 
behaviour returned to that in the status quo scenario. 
Individuals who had an HIV test in the previous 
6 months or who were already receiving antiretroviral 
therapy were not retested by the intervention. Home 
HTC was modelled to reach 92% of women and 79% of 
men (on the basis of numbers of ineligible individuals 
from the ﬁ eld studies), taking into account migration for 
work. Condom use could increase after a positive HIV 
test (appendix).
We separated the intervention into constituent parts 
(increased testing, linkage to care, and antiretroviral 
therapy initiation) and estimated the contribution of each 
element to the overall eﬀ ect.
We did 5000 model simulations for each scenario. We 
present summary results over 10 years as the median 
outcome bounded by the 5th and 95th percentiles 
(encompassing 90% of variability in model outputs).
Cost analysis
We did a microcosting study in KwaZulu-Natal, 
South Africa, to derive home HTC costs during an 
ongoing community-based HTC trial (table 1).35 We 
adopted a provider perspective and collected costs from 
interviews with staﬀ  and local experts, budgets, expense 
reports, and travel logs. We did a mixture of ingredient-
based and activity-based costing. We divided costs into 
mutually exclusive categories of personnel, trans-
portation, equipment, supplies, buildings and overhead, 
start-up, recurring meetings, and data capture and use. 
We did time-and-motion studies to determine staﬀ  time 
spent on intervention activities (to estimate the mean 
Unit cost (2012 US$)
HIV testing and linkage to care $20 per diagnostic test
Pre-antiretroviral therapy care
CD4 count ≤200 cells per μL $359 per person-year
CD4 count 201–350 cells per μL $238 per person-year
CD4 count >350 cells per μL $205 per person-year
Initiation of antiretroviral therapy
Patients in pre-antiretroviral therapy care $95 per initiation*
Patients not in pre-antiretroviral therapy care $126 per initiation
Antiretroviral therapy provision $565 per person-year
Health-care use for HIV-positive people not linked to care
CD4 count ≤200 cells per μL $167 per person-year
CD4 count 201–350 cells per μL $46 per person-year
CD4 count >350 cells per μL $13 per person-year
End-of-life care $160 per death
Supply-chain management and programmatic support
Supply-chain management 20% mark-up on all antiretroviral therapy costs
Programmatic support† 50% mark-up on all non-antiretroviral therapy costs
Table based on data from Eaton and colleagues.33 *In the scenario of universal antiretroviral therapy, pretreatment 
costs represent health-care costs incurred before initiation of antiretroviral therapy, including assessment of liver, 
kidney, and bone marrow function. †The mark-up for programmatic support applies to non-intervention costs only.
Table 2: Unit costs for all other health-care costs in South Africa
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Figure 2: Modelled coverage of antiretroviral therapy
Antiretroviral therapy coverage among all HIV-positive individuals over the 10 years after home HTC with changes 
in antiretroviral therapy eligibility criteria. ART=antiretroviral therapy. HTC=HIV counselling and testing.
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number of visits that could feasibly be done each day), 
and to assess research time costs (time spent obtaining 
informed consent, reimbursements, etc). We annualised 
capital costs, software development, and start-up costs 
(eg, staﬀ  hiring, training, and community mobilisation) 
assuming a usable life of 5 years. Costs were discounted 
annually at 3%. We based background costs of HIV 
testing and linkage, health-care use, and antiretroviral 
therapy on estimates for South Africa (table 2).33
We deﬁ ned three cost models to assess the importance 
of key assumptions. The ﬁ rst represented the actual costs 
of the research study, including staﬀ  and equipment 
used in the pilot study. The second was an operational 
costing model, omitting research-related costs, assuming 
task shifting from professional counsellors to lay staﬀ  
(eg, community care workers), and increasing testing 
eﬃ  ciency and using government salaries instead of 
research salaries for staﬀ  (table 1). The third was an 
operational costing model with reduced costs for 
antiretroviral therapy in South Africa (decreasing cost 
estimates for antiretroviral therapy from $565 per 
person-year for total related and non-related costs33 to a 
target ﬁ gure of $200 per person-year, the target 
antiretroviral therapy price for low-resource settings36).
Cost-eﬀ ectiveness analysis
We calculated the incremental cost-eﬀ ectiveness ratio 
(ICER) of home HTC compared with the status quo for 
both HIV infections and DALYs averted for all simulated 
criteria for antiretroviral therapy initiation. Sensitivity 
analyses were done around the discount rate for costs 
and DALYs averted. All simulations and calculations 
were done in MATLAB version 2011b.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Figure 3: Health eﬀ ects of home HTC with increasing eligibility criteria for antiretroviral therapy
Median incidence and DALYs accrued over 10 years in the model population of mean initial size of 10 000 individuals. In panels B and D, household testing represents 
immediate HIV testing for all home HTC recipients but no explicit increase in clinic attendance or antiretroviral therapy initiation rates; facilitated linkage to care 
represents the increase in clinic attendance for HIV-positive individuals following home HTC; and antiretroviral therapy uptake represents the rate of initiation 
treatment for HIV-positive individuals who are eligible under the modelled guidelines. Error bars represent 90% model variability. (A) Total population incidence 
averaged over 10 years (mean of 5000 simulations). (B) Decrease in incidence between the baseline scenario (facility-based testing) and the intervention scenario 
(facility-based testing plus home HTC intervention); ﬁ gure shows percentage reduction (mean of 5000 simulations) and contribution of diﬀ erent elements of the 
intervention in the model (mean of 500 simulations). (C) Total DALYs accrued over 10 years (mean of 5000 simulations). (D) DALYs averted between the baseline 
scenario (facility-based testing) and the intervention scenario (facility-based testing plus home HTC intervention); ﬁ gure shows percentage reduction (mean of 
5000 simulations) and contribution of diﬀ erent elements of the intervention in the model (mean of 500 simulations). HTC=HIV counselling and testing. 
DALY=disability-adjusted life-year. ART=antiretroviral therapy.
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Results
Antiretroviral therapy coverage varied with modelled 
eligibility criteria (ﬁ gure 2). In the status quo scenario 
with antiretroviral therapy eligibility of 200 CD4 cells per 
μL or lower, coverage fell from 32% to 29% (90% model 
variability 27–30) of HIV-infected individuals over 
10 years. Changing of antiretroviral therapy guidelines to 
350 cells per μL or lower, 500 cells per μL or lower, and 
universal antiretroviral therapy increased the coverage to 
45% (90% model variability 43–46), 49% (47–50), and 
52% (50–54) in the status quo scenarios. Home HTC 
increased coverage to 39% (90% model variability 37–41), 
63% (61–64), 71% (70–72), and 78% (77–79) with 
increasing antiretroviral therapy eligibility.
With no intervention, increased antiretroviral therapy 
threshold alone reduced incidence by 10–21% as 
eligibility increased (ﬁ gure 3). Home HTC reduced HIV 
incidence by 9–48% depending on the antiretroviral 
therapy threshold (ﬁ gure 3). The large decreases in 
incidence at high eligibility thresholds for antiretroviral 
therapy are possible because many individuals are tested 
at higher CD4 cell counts, allowing high linkage to care 
and viral suppression. Total reduction in incidence was 
mainly driven by facilitated linkage to care (5–21% with 
increasing eligibility for antiretroviral therapy; ﬁ gure 3).
Increased eligibility for antiretroviral therapy also 
reduced DALYs; moving the threshold to 350 cells per μL 
averted 15%, 500 cells per μL averted 23%, and universal 
antiretroviral therapy averted 27% compared with the 
threshold of 200 cells per μL (ﬁ gure 3). Home HTC 
reduced DALYs by 10–22% with increasing eligibility for 
antiretroviral therapy (ﬁ gure 3). The main contribution 
to DALYs averted was increased uptake of antiretroviral 
therapy (6–10% with increasing antiretroviral therapy 
eligibility; ﬁ gure 3).
Antiretroviral therapy costs were a major driver of the 
total programme costs, contributing 24–87% of total 
costs depending on eligibility criteria (ﬁ gure 4). The 
second-largest contributor to total costs was pretreatment 
costs, including clinical and laboratory testing, and 
prophylaxis and treatment for opportunistic infections 
(5–55% with decreasing antiretroviral therapy eligibility). 
HTC, antiretroviral therapy initiation, end-of-life care, 
and other health-care costs for HIV-infected individuals 
not linked to HIV care contributed little to overall costs 
(<12% each).
The undiscounted additional cost of implementation of 
home HTC compared with the status quo, for 
10 000 adults over 5 years, ranged from $1·57 million 
(90% model variability $1·44 million to $1·69 million) 
for an antiretroviral therapy eligibility threshold of 
200 cells per μL or lower to $2·93 million ($2·77 million 
to $3·11 million) for universal antiretroviral therapy 
(assuming the operational cost model with current 
antiretroviral therapy prices). Implementation of home 
HTC was more costly than facility-based testing alone 
over the 10 year analysis, and did not become cost-saving 
within this timeframe.
The baseline scenario, with antiretroviral therapy 
eligibility at 200 cells per μL or lower and the research 
costing model (ﬁ gure 5), produced median ICER values of 
$22 000 per HIV infection averted (90% model variability 
$11 300–75 900) and $1340 per DALY averted ($1080–1760). 
A small proportion (2·0%) of the ICER distribution for the 
incremental cost per infection averted with antiretroviral 
Figure 4: Breakdown of total programme costs
Total programme costs accrued over 10 years for the baseline and home HTC model scenarios for a population of 
mean initial size of 10 000 individuals. (A) Research costing model. (B) Operational costing model with high ART 
costs. (C) Operational model with low ART costs. HTC=HIV counselling and testing. ART=antiretroviral therapy.
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therapy eligibility at 200 cells per μL or lower were located 
in the northwest quadrant of the cost-eﬀ ectiveness plane 
(ﬁ gure 5). The incremental cost per infection averted 
seemed to decrease with expanding eligibility for 
antiretroviral therapy, but we did not note any clear trend 
for the incremental cost per DALY averted (ﬁ gure 5).
The research and operational models with high 
antiretroviral therapy costs resulted in similar ICER values 
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Figure 5: Incremental cost-eﬀ ectiveness ratios
Figure shows ICERs comparing home HTC with status quo at each threshold for antiretroviral therapy initiation. Panels A and B show median of 5000 simulations, 
with median cost plotted against median eﬀ ect. Ellipses contain 95% of 5000 simulations; error bars show 90% of the variability in model outputs (5th to 
95th percentiles). (A) Infections averted. (B) DALYs averted. (C) Infections averted, by cost model. (D) DALYs averted, by cost model. ICER=incremental cost-
eﬀ ectiveness ratio. HTC=HIV counselling and testing. ART=antiretroviral therapy. 
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at all antiretroviral therapy eligibilities. By contrast, 
decreased cost of antiretroviral therapy reduced ICERs 
substantially. For example, the ICER per DALY averted was 
reduced from $1300 (90% model variability $1140–1510) 
with high costs to $310 ($265–369) at a lower cost, 
assuming universal antiretroviral therapy (ﬁ gure 5). 
Furthermore, with low antiretroviral therapy cost, the 
trend in ICER values with expansion of eligibility criteria 
for antiretroviral therapy decreased such that antiretroviral 
therapy for all HIV-positive individuals became the most 
cost-eﬀ ective strategy, although model variability was high.
Sensitivity analyses showed that application of a 
3% discount rate to DALYs or varying the cost discount 
rate from 0% to 12% did not change the qualitative 
results (appendix).
Discussion
Expansion of antiretroviral therapy uptake through 
home HTC is cost eﬀ ective, with ICERs driven mainly 
by the cost of drugs. When antiretroviral therapy prices 
decrease, more expensive testing and linkage strategies, 
including home HTC, are more likely to be economically 
viable (panel). Increases in HIV testing and antiretroviral 
therapy uptake reported from ﬁ eld studies of home HTC 
have the potential to translate into substantial reductions 
in HIV morbidity and mortality, and are cost eﬀ ective at 
all eligibility criteria for antiretroviral therapy. Our 
analysis also shows that raising the CD4 count threshold 
for initiation of antiretroviral therapy from 350 cells 
per μL to 500 cells per μL could reduce HIV incidence by 
6·6% and avert 9·1% of DALYs compared with current 
practice. However, the potential eﬀ ect of changes in 
guidelines might not be fully realised because of low 
rates of HIV testing for individuals with high CD4 cell 
counts. By bringing HTC services into the community, 
home HTC increases testing and linkage to care, thus 
helping to maximise the number of people beneﬁ ting 
from changes to guidelines. Our ﬁ ndings suggest that 
raising antiretroviral therapy eligibility from 350 cells 
per μL to 500 cells per μL with home HTC would reduce 
incidence by 20% and avert 13% of DALYs. The eﬀ ect of 
home HTC seems greater on infections than on DALYs 
averted over the 10 year timeframe because 
the probability of HIV transmission from all infected 
individuals on antiretroviral therapy was reduced, 
irrespective of their CD4 counts. By contrast, anti-
retroviral therapy initiation produced a small reduction 
in morbidity in the model for individuals with CD4 
counts of 350 cells per μL and above, because the 
disability weights were the same and reductions in 
mortality did not have a substantial eﬀ ect within the 
10 year timeframe of this analysis.33
With current prices for antiretroviral therapy in South 
Africa, total programme costs are driven by the lifetime 
costs of antiretroviral therapy. Therefore, neither the 
removal of research-related costs nor task shifting 
substantially aﬀ ected cost-eﬀ ectiveness in our analyses. 
Even with use of research costs, the most expensive 
costing model, ICERs per DALY averted are 14–19% (and 
upper bounds <25%) of the $7350 gross domestic 
product per person for South Africa in 2012, and can 
therefore be classed as very cost eﬀ ective.44 ICERs are 
more favourable when antiretroviral therapy costs are 
decreased to be similar to global standards,36 which could 
reduce the cost per DALY averted in this programme by 
36–76%. This scenario would make home HTC a 
ﬁ nancially attractive option, particularly at high anti-
retroviral therapy eligibility criteria.
Our results are robust to changes in task-shifting 
assumptions, antiretroviral therapy costs, and dis-
counting of rates for costs and health beneﬁ ts. They are 
similar to those from a previous cost-eﬀ ectiveness 
analysis27 done in South Africa, showing that community 
HTC implemented through mobile vans was very cost 
eﬀ ective.
A major strength of this analysis is the pairing of 
primary data for home testing in South Africa with a 
detailed model of HIV transmission parameterised from 
the same study. The model includes detailed data about 
demographics, risk behaviour, CD4 distribution, 
Panel: Research in context 
Systematic review
We searched PubMed and Embase for health economic analyses of community-based HIV 
counselling and testing (HTC) and linkage to care published between Jan 1, 2000, and 
June 12, 2014, with the terms “HIV” AND “Africa South of the Sahara” AND (“mass 
screening” OR “testing” OR “screen” OR “diagnosis” OR “counseling”) AND “cost”. Our results 
included a 2013 systematic review10 which emphasised the heterogeneity between cost-
eﬀ ectiveness studies; these studies are diﬃ  cult to compare because they include diﬀ erent 
intervention components delivered via diﬀ erent approaches and costs vary by country and 
HIV prevalence. We identiﬁ ed 127 abstracts, of which eight studies met our inclusion criteria 
of community HTC costing studies conducted in sub-Saharan Africa that included testing 
supplies, personnel, and start-up costs in their estimates.26–28,37–41 Costs ranged from 
US$29·30–31·30 for mobile van HTC in South Africa to $5·00–8·29 for home HTC in 
Uganda.37,41 Church-based HTC in South Africa was found to range from $81·72 to $126·48 
(including testing supplies, personnel, utilities, training, buildings, oﬃ  ce equipment, and 
publicity).25,26 Averaging across all community HTC strategies, we estimate a cost of 
$25·00 per person tested (2012 US$) in sub-Saharan Africa. Mathematical modelling has 
increasingly been used to support analyses of eﬀ ects and cost-eﬀ ectiveness of changing 
treatment policy (recently reviewed by Ying and colleagues42), but to our knowledge this 
analysis is the most detailed pairing of mathematical modelling with cost data for home-
based testing done so far. We anticipate with interest the cost-eﬀ ectiveness analyses that will 
accompany the large community-randomised controlled trials that are underway,21–24 some 
of which are already using mathematical models to inform and monitor progress.43
Interpretation
Our ﬁ ndings suggest that home-based HIV testing and counselling for HIV, together with 
community mobilisation and sensitisation, point-of-care CD4 testing, screening for clinical 
indicators for antiretroviral therapy initiation, and follow-up visits by a community health 
worker (to support antiretroviral therapy uptake and adherence) can substantially decrease 
HIV infections and morbidity when implemented at high coverage. Our cost-eﬀ ectiveness 
analyses add to the growing body of evidence that intensive community-based testing 
strategies will require additional resources but can also be cost eﬀ ective.
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